Abstract 2108P
Background
Vitamin B12 impairment is common in cancer patients due to several factors, namely gastrointestinal (GI) surgery, malnutrition, liver metastases, and chemotherapy. Data regarding their prevalence and significance in this setting, as well as the impact on the overall prognosis, are lacking.
Methods
We retrospectively enrolled patients hospitalized for various cancer-related conditions at our Medical Oncology ward (2017-2022). Plasma B12 levels were stratified as Very Low (VL <200 pg/ml), Low (L 200-300 pg/ml), Normal (N 300-813 pg/ml) or High (H >813 pg/ml). We collected demographic and clinical data, including BMI, Cumulative Illness Rating Scale, nutritional status, ECOG PS, primary cancer site, disease stage, liver involvement and function tests, GI surgery. Univariate and multivariate statistical tests identified variables statistically associated to vitamin B12 (p<0.05).
Results
We enrolled 788 patients (F/M: 1.05, median age: 72, IQR: 62-78 y), VL B12 levels were found in 14.09% cases, L in 19.42%, N in 49.37% and H in 17.13%. At univariate analysis, B12 distribution was significantly different between genders, with females being characterized by higher median values compared to males. Vitamin B12 distribution increased significantly as function of ECOG PS levels. Breast cancer patients were characterized by the highest median B12 value while colorectal cancer patients by the lowest. B12 was also significantly higher in advanced compared to early-stage patients as well as in those who had liver failure. The correlation between B12 and age, albumin, prealbumin, total protein and folates was statistically significant but negligible (|r|<0.3). Multivariate analysis showed that the probability of H vs VL B12 levels was increased in patients with hypoproteinemia, hypoprealbuminemia and ECOG PS≥2, and decreased in those with colorectal and gastric cancer
Conclusions
To our knowledge, this is the first study investigating B12 levels in a wide and well clinically-characterized group of cancer patients; our data suggest that increased B12 is associated to an impaired clinical status, while in early stage patients, especially the elderly, B12 deficiency is of concern and may negatively impact the overall outcomes.
Clinical trial identification
#2734CE, released on the 31/01/2023.
Editorial acknowledgement
Legal entity responsible for the study
IRCCS Pavia - Istituti Clinici Scientifici Maugeri.
Funding
Has not received any funding.
Disclosure
A. Malovini: Financial Interests, Personal, Stocks/Shares: Biomeris S.R.L. L.D. Locati: Financial Interests, Institutional, Speaker, Consultant, Advisor: Lilly, Eisai, MSD, Ipsen, Bayer, Roche, Gentili SrL. All other authors have declared no conflicts of interest.
Resources from the same session
2065P - Communication on the first medical oncology appointment: What do cancer patients want?
Presenter: Rodrigo Vicente
Session: Poster session 06
2066P - Evaluation of the quality and reliability of ChatGPT and Perplexity's responses about rectal cancer
Presenter: Ozan Yazici
Session: Poster session 06
2067P - Influence of psychiatric disorders on survival in patients with lung cancer: Real-world data
Presenter: Tomi Kovacevic
Session: Poster session 06
2068P - Perspectives and concerns on sexuality among adolescents and young adults treated for testicular germ cell tumour: The PRICELESS-study - A qualitative study
Presenter: Danielle Zweers
Session: Poster session 06
2069P - QoL changes of caregivers during first-line palliative chemotherapy for patients with incurable cancer
Presenter: Nobumichi Takeuchi
Session: Poster session 06
2070P - Assessment of healthy lifestyle habits in breast cancer patients
Presenter: Juan Cristobal Sanchez
Session: Poster session 06
2071P - Identification of top issues and concerns of cancer patients in Korea on social media
Presenter: Joo Han Lim
Session: Poster session 06
2072P - Topical application of mixed agents to reduce oral mucositis during radiotherapy in post operated head and neck cancer
Presenter: Chandra Prakash
Session: Poster session 06
2073P - Medical cannabis: A potential effective treatment for chemotherapy-induced peripheral neuropathy (CIPN)
Presenter: Ravit Geva
Session: Poster session 06
2074P - Oral cannabidiol for prevention of chemotherapy-induced peripheral neuropathy
Presenter: Sebastian Nielsen
Session: Poster session 06